NVZMY News and Press, Novozymes A/S ADR From 10/10/23

2023-10-10 21:54:11 ET Summary Novozymes' stock is declining for almost two years and has lost almost 50% of its previous value. The company reported mediocre half-year results for fiscal 2023. But Novozymes has a wide economic moat around its business, making the company a go...

2023-10-09 12:37:47 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

Novozymes Named EPA Safer Choice Partner of the Year for Third Year in a Row PR Newswire World's Leading Biotech Powerhouse Recognized for Providing and Advocating for Ingredients that Create Safer Detergents FRANKLINTON, N.C. , Oct. 3, 2023 /PRNewswire/ ...

2023-08-09 14:05:09 ET Novozymes A/S (NVZMF) 1H 2023 Earnings Conference Call August 9 2023 3:00 AM ET Company Participants Tobias Bjorklund - Head of investor relations Ester Baiget - President and CEO Lars Green - EVP and CFO Amy Byrick - EVP, Strategy and ...

2023-08-09 00:36:25 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-07-17 08:45:23 ET Summary Novozymes is increasing prices to counter soft demand and high costs, but end markets probably won't tolerate rising prices indefinitely. With generally weak input price inflation, Novozymes' stock price is likely to be determined by the interplay of...

2023-07-07 11:07:45 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-06-02 05:36:23 ET Summary Danish companies Novozymes and Christian Hansen have announced plans to merge, creating a leading global biosolutions company. The merger is expected to be completed in late 2023 or early 2024, following regulatory approval. Despite the wide econ...

2023-05-09 23:17:21 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-04-26 21:11:04 ET Novozymes A/S (NVZMF) Q1 2023 Earnings Conference Call April 26, 2023, 03:00 ET Company Participants Tobias Bjorklund - Head of IR Ester Baiget - President & CEO Lars Green - EVP & CFO Amy Byrick - EVP, Strategy & Business T...